Cargando…

PROSTATE-SPECIFIC ANTIGEN (PSA) VALUES IN PATIENTS WITH LOW- AND HIGH-RISK PROSTATIC ADENOCARCINOMA

Prostatic adenocarcinoma (PC) comprises around 19% of malignancies in Croatian male population. On the basis of PSA value, Gleason score, grading group and clinical stage, PC can be classified into low- and high-risk groups which is significant for different therapeutic regimens and prognostic outco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mašić, Silvija, Pezelj, Ivan, Krušlin, Božo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 2019
Materias:	Original Scientific Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693563/ https://www.ncbi.nlm.nih.gov/pubmed/34975192 http://dx.doi.org/10.20471/acc.2019.58.s2.02

Ejemplares similares

CORRELATION OF EXPRESSION OF TGF- β AND MMP2 BETWEEN PROSTATIC ADENOCARCINOMA AND ADJACENT UNAFFECTED PARENCHYMA
por: Mašić, Silvija, et al.
Publicado: (2022)

COMPARISON OF GRADING ACCURACY OF PROSTATE CANCER IN SAMPLES ACQUIRED BY A TARGETED AND SYSTEMIC PROSTATE BIOPSY
por: Pezelj, Ivan, et al.
Publicado: (2022)

Prostate Cancer—Focus on Cholesterol
por: Škara, Lucija, et al.
Publicado: (2021)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

The Association between Prostate-Specific Antigen Velocity (PSAV), Value and Acceleration, and of the Free PSA/Total PSA Index or Ratio, with Prostate Conditions
por: Flores-Fraile, María-Carmen, et al.
Publicado: (2020)

Prostate biopsy for elevated prostate specific antigen (PSA) – Indian perspective
por: Ragavan, N.
Publicado: (2014)

Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma
por: Yin, Ming, et al.
Publicado: (2007)

Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
por: LIU, Xin, et al.
Publicado: (2015)

Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)
por: Stephan, Carsten, et al.
Publicado: (2014)

Definition of Outcome-Based Prostate-Specific Antigen (PSA) Thresholds for Advanced Prostate Cancer Risk Prediction
por: Ferraro, Simona, et al.
Publicado: (2021)

Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers
por: Filella, Xavier, et al.
Publicado: (2016)

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
por: Azab, Sherif, et al.
Publicado: (2012)

Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
por: Cho, Hyungseok, et al.
Publicado: (2022)

Prostate-Specific Antigen (PSA) and Prostate Volume: Better Predictor of Prostate Cancer for Bosnian and Herzegovina Men
por: Coric, Jozo, et al.
Publicado: (2015)

Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
por: Koo, Jin Mo, et al.
Publicado: (2010)

Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer
por: Chavan, Sushant V., et al.
Publicado: (2014)

The effect of the frequency and duration of prostate specific antigen (PSA) measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer
por: Paller, CJ, et al.
Publicado: (2013)

Permanent (125)I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence
por: Mazeron, Renaud, et al.
Publicado: (2012)

Utility of Free/Total Prostate Specific Antigen (f/t PSA) Ratio in Diagnosis of Prostate Carcinoma
por: Thakur, V., et al.
Publicado: (2004)

Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline
por: Tikkinen, Kari A O, et al.
Publicado: (2018)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

Prostate cancer stroma: an important factor in cancer growth and progression
por: Krušlin, Božo, et al.
Publicado: (2015)

Outcome of Prostate Biopsy in Men Younger than 40 Years of Age with High Prostate-Specific Antigen (PSA) Levels
por: Yang, Jin Bak, et al.
Publicado: (2010)

Proteolytic Activity of Prostate-Specific Antigen (PSA) towards Protein Substrates and Effect of Peptides Stimulating PSA Activity
por: Mattsson, Johanna M., et al.
Publicado: (2014)

Using a Recurrent Neural Network To Inform the Use of Prostate-specific Antigen (PSA) and PSA Density for Dynamic Monitoring of the Risk of Prostate Cancer Progression on Active Surveillance
por: Sushentsev, Nikita, et al.
Publicado: (2023)

Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer
por: Lehrer, S, et al.
Publicado: (2002)

Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis
por: Ilic, Dragan, et al.
Publicado: (2018)

Mutations in the prostate specific antigen (PSA/KLK3) correlate with male infertility
por: Gupta, Nishi, et al.
Publicado: (2017)

The value of percentage free prostate specific antigen (PSA) in the detection of prostate cancer among patients with intermediate levels of total PSA (4.0–10.0 ng/mL) in Nigeria
por: Ezenwa, E.V., et al.
Publicado: (2012)

Molecular Form Differences Between Prostate-Specific Antigen (PSA) Standards Create Quantitative Discordances in PSA ELISA Measurements
por: McJimpsey, Erica L.
Publicado: (2016)

Does prostate-specific antigen (PSA) mass or free PSA mass improve the accuracy of predicting total prostate volume in relation to obesity in men with biopsy-proven benign prostatic hyperplasia?
por: Jung, Jin-Woo, et al.
Publicado: (2019)

Serum Fucosylated Prostate-specific Antigen (PSA) Improves the Differentiation of Aggressive from Non-aggressive Prostate Cancers
por: Li, Qing Kay, et al.
Publicado: (2015)

Prostate-specific antigen (PSA) and distress: - a cross-sectional nationwide survey in men with prostate cancer in Sweden
por: Rönningås, Ulrika, et al.
Publicado: (2019)

Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models
por: Chen, Ming, et al.
Publicado: (2021)

Usefulness of Total PSA Value in Prostate Diseases Diagnosis
por: Prcic, Alden, et al.
Publicado: (2016)

MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia
por: Abramovic, Irena, et al.
Publicado: (2021)

Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0–10.0 ng/ml
por: Chen, Rui, et al.
Publicado: (2015)

A population study of fasting time and serum prostate-specific antigen (PSA) level
por: Lau, Cheryl K, et al.
Publicado: (2014)

Raising cut-off value of prostate specific antigen (PSA) for biopsy in symptomatic men in India to reduce unnecessary biopsy
por: Agnihotri, Shalini, et al.
Publicado: (2014)

Value of free/total prostate-specific antigen (f/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10 ng/mL: A meta-analysis
por: Huang, Yan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m83lnq4k6h6dm9vme70aaec950